Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Intensive fibrosarcoma-binding capability of the reconstituted analog and its antitumor activity

Drug Delivery(2018)10.1080/10717544.2017.1410261Source: DataRank Database

Intensive fibrosarcoma-binding capability of the reconstituted analog and its antitumor activity is a research paper published in Drug Delivery (2018). On theSindex it has a DataRank of 0.292. It has been cited 6 times.

N/A

0.292DataRank · unranked

Scored on demand from live citation data

6 citations

Download PDF

Cite:

Linked data & code

doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (3 grants)Impact (FWCI 0.51)OA: goldTopics (54)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (0/2)

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 100%Citation Network 0%

Base Score Contribution

0.292

From this paper's citation signal

Citation Network Contribution

Citation network not refreshed for this result

This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.

Learn more about DataRank methodology →

Authors (11)

Yue Du ORCID,Wen-Juan Liu,Liang Li ORCID,Yi Li ORCID,Xiao-Fei Wang

Live enrichment

PubMed:29250984 PMC:PMC6058573 OpenAlex:https://openalex.org/W2777232569

CAMS

Grant: 2016-I2M-3-013

Significant New Drug Development’ Major Science and Technology Development

Grant: . 2014ZX09201042-003

National Key Research and Development

Grant: 2016YFA0201504

FWCI

0.51

Citation Percentile

0.6%

Citation Trend

2018

2019

2024

goldLicense: cc-by

journalhttps://www.tandfonline.com/doi/pdf/10.1080/10717544.2017.1410261?needAccess=true

GOLDhttps://www.tandfonline.com/doi/pdf/10.1080/10717544.2017.1410261?needAccess=true

publisherhttps://www.tandfonline.com/doi/pdf/10.1080/10717544.2017.1410261?needAccess=true

publisherhttps://tandfonline.com/doi/pdf/10.1080/10717544.2017.1410261

publisherhttps://www.tandfonline.com/doi/pdf/10.1080/10717544.2017.1410261

Fields of Study

Histone Deacetylase Inhibitors ResearchPeptidase Inhibition and AnalysisSynthetic Organic Chemistry MethodsMedicineA549 CellsAnimalsAntineoplastic AgentsApoptosisCell Cycle CheckpointsCell Line, TumorCell MovementCell ProliferationFibrosarcomaG2 Phase Cell Cycle CheckpointsHumansMatrix MetalloproteinasesMiceMice, Inbred BALB CMice, NudeTissue Inhibitor of Metalloproteinase-2

MeSH Terms

A549 CellsAnimalsAntineoplastic AgentsCell MovementFibrosarcomaHumansMice, Inbred BALB CMice, NudeApoptosisTissue Inhibitor of Metalloproteinase-2Matrix MetalloproteinasesCell Line, TumorCell ProliferationMiceCell Cycle CheckpointsG2 Phase Cell Cycle Checkpoints

Keywords

HT1080FibrosarcomaMatrix metalloproteinaseCancer researchEnediyneCytotoxicityPharmacologyMaterials scienceMedicineChemistryIn vitroBiochemistryPathologyStereochemistryEvaluationDrug DeliveryTreatment EfficacyBinding Capability

Sustainable Development Goals

SDG 0: Good health and well-being

Intensive fibrosarcoma-binding capability of the reconstituted analog and its antitumor activity

FAIR Checklist

DataRank Breakdown

Authors (11)

Funding (3 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)